Provided by Tiger Trade Technology Pte. Ltd.

Janux Therapeutics, Inc.

18.60
0.0000
Volume:692.24K
Turnover:13.05M
Market Cap:1.14B
PE:-11.32
High:19.14
Open:18.75
Low:18.59
Close:18.60
52wk High:35.34
52wk Low:12.12
Shares:61.14M
Float Shares:49.82M
Volume Ratio:0.77
T/O Rate:1.39%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.6429
EPS(LYR):-1.8336
ROE:-10.70%
ROA:-8.80%
PB:1.23
PE(LYR):-10.14

Loading ...

Janux VP Accounting Maria Dobek sells 2,038 shares worth $28,874.46

Reuters
·
May 14

Janux Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
May 08

Wedbush Adjusts Janux Therapeutics Price Target to $36 From $45, Maintains Outperform Rating

MT Newswires Live
·
May 08

Janux Therapeutics Is Maintained at Buy by Guggenheim

Dow Jones
·
May 08

Guggenheim Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)

TIPRANKS
·
May 08

Janux Therapeutics price target lowered to $26 from $30 at Piper Sandler

TIPRANKS
·
May 08

Analysts Offer Insights on Healthcare Companies: Omada Health, Inc. (OMDA), Janux Therapeutics Inc (JANX) and Progyny (PGNY)

TIPRANKS
·
May 08

Analyst Reiterates Buy on Janux, Citing Pipeline Upside and Key 2027 Catalyst; Price Target Maintained at $14

TIPRANKS
·
May 08

Janux Therapeutics: Strong Balance Sheet and Advancing PSMA Pipeline Underpin Buy Rating and Favorable Risk-Reward

TIPRANKS
·
May 08

Janux Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 08

Janux Therapeutics Q1 EPS $(0.39) Beats $(0.53) Estimate, Sales $3.733M Miss $3.833M Estimate

Benzinga Earnings
·
May 08

Janux Q1 FY26 net loss widens to $24.4 million; R&D expenses rise to $26.8 million

Reuters
·
May 08

BRIEF-Janux Therapeutics Q1 Basic EPS USD -0.39

Reuters
·
May 08

Janux Therapeutics Q1 Net Income USD -24.361 Million

THOMSON REUTERS
·
May 08

Janux Therapeutics Q1 Operating Expenses USD 37.946 Million

THOMSON REUTERS
·
May 08

Guggenheim Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX)

TIPRANKS
·
Apr 29

Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), Stryker (SYK) and CareDx (CDNA)

TIPRANKS
·
Apr 29

Janux Therapeutics Adjusts Board Class Structure for Director

TIPRANKS
·
Apr 29

Janux reclassifies Eric Dobmeier as Class II director, keeps him on compensation committee

Reuters
·
Apr 29

Janux Therapeutics announces annual shareholder meeting notice

Reuters
·
Apr 29